Business Wire - Research and Markets: The Parkinsons Disease Market Is Set To Continue To Grow Over The Next 7 Years, Reaching Over $2.37 Billion In 2013, A 39% Increase From…
DUBLIN, Ireland — Research and Markets (http://www.researchandmarkets.com/reports/c72211) has announced the addition of “Pipeline and Commercial Insight: Parkinsons Disease - Market to grow as first round of lifecycle management strategies” succeed to their offering.
Introduction
The PD market is set to continue to grow over the next 7 years, reaching over $2.37 billion in 2013, a 39% increase from 2006 levels. Combinations, reformulations, and indication expansions will drive the majority of this growth, with key brands expected to be Novartis/Orions Stalevo, GlaxoSmithKlines (GSKs) Requip Modutab, and UCB-Schwarzs Neupro.
Scope
Related Results
GSK faces approval delay.
GSK wins restless leg race
Research and Markets: The Parkinsons Disease Market Is Set To Continue To Gro…
PPSI wins SW Argus press revamp work
Pinguin sauve une usine anglaise de legumes surgeles. (En Manchete Dans Ce Nu…
Analysis of patient potential, unmet needs and clinical trial design in PD Overview of key marketed brands, late- and early-stage pipeline drugs, and cell/gene therapies. Indication- and country-specific sales volume and value forecasts to 2016 of marketed brands, generics, and key late-stage pipeline drugs. Identification of future market events that are expected to affect PD drug revenues.
Highlights
GSKs Requip Modutab will become the market leading PD brand in 2011. It will be intuitive for prescribers to believe that sustained activation of dopamine receptors with Requip Modutab could have a significant clinical benefit over pulsed agonism with standard drugs. New pipeline drugs will need to be innovative to compete in an increasingly crowded market. While this is evident in Eisais E2007, it is lacking in Merck-Serono/Newrons safinamide. Early studies with cell/gene therapies show great promise for significantly slowing the progression of the disease. However, these alternative approaches will not significantly impact the sales of pharmaceuticals over the forecast period 2007-2016.
Reasons to Purchase
Benchmark key late-stage PD compounds against current market leading brands. Assess country-specific (US, Japan, France, Germany, Italy, Spain and the UK) sales forecasts of key late-stage pipeline drugs and marketed brands. Understand unmet needs and opportunities in the PD market based on key opinion leader comments.
For more information, visit http://www.researchandmarkets.com/reports/c72211
Source: Datamonitor
COPYRIGHT 2007 Business Wire
COPYRIGHT 2008 Gale, Cengage Learning
